The meeting was focused on discussing Anixa's Cchek test, an artificial intelligence based liquid biopsy for the early detection of cancer.
Anixa Biosciences expects the official minutes of the Pre-Sub meeting to be available in January. On January 24, 2019 Anixa plans to hold a conference call where it will discuss the commercialization path and timeline for Cchek-Prostate, as well as an update on its CAR-T therapeutics program.
Shares are up 2% premarket.
Subscribe for full text news in your inbox